Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 1, 2009, Pages 67-73

  Steinmetzer, Torsten ^a,b   Dönnecke, Daniel ^a   Korsonewski, Martin ^a   Neuwirth, Claudia ^a   Steinmetzer, Peter ^a   Schulze, Alexander ^a   Saupe, Sebastian Martin ^b   Schweinitz, Andrea ^a  

^a Curacyte Discovery GmbH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Anticancer drugs; Matriptase; Protease inhibitor; Serine protease; Suzuki coupling

Indexed keywords

3 AMIDINOPHENYLALANINE DERIVATIVE; MATRIPTASE; MATRIPTASE INHIBITOR; PHENYLALANINE DERIVATIVE; SERINE PROTEINASE INHIBITOR; THROMBIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; REACTION ANALYSIS;

AMIDINES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 57749087821     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.019     Document Type: Article

References (31)

1. For reviews, see:. Netzel-Arnett S., Hooper J.D., Szabo R., Madison E.L., Quigley J.P., Bugge T.H., and Antalis T.M. Cancer Metastasis Rev. 22 (2003) 237
2. Szabo R., and Bugge T.H. Int. J. Biochem. Cell Biol. 40 (2008) 1297
3. Shi Y.E., Torri J., Yieh L., Wellstein A., Lippman M.E., and Dickson R.B. Cancer Res. 53 (1993) 1409
4. Lin C.-Y., Anders J., Johnson M., and Dickson R.B. J. Biol. Chem. 274 (1999) 18237
5. List K., Haudenschild C.C., Szabo R., Chen W., Wahl S.M., Swaim W., Engelholm L.H., Behrendt N., and Bugge T.H. Oncogene 21 (2002) 3765
6. Uhland K. Cell. Mol. Life Sci. 63 (2006) 2968
7. List K., Szabo R., Molinolo A., Sriuranpong V., Redeye V., Murdock T., Burke B., Nielsen B.S., Gutkind J.S., and Bugge T.H. Genes Dev. 19 (2005) 1934
8. Lee S.-L., Dickson R.E., and Lin C.-Y. J. Biol. Chem. 275 (2000) 36720
9. Rockway T.W., Nienaber V., and Giranda V.L. Curr. Pharm. Design 8 (2002) 2541
10. Steinmetzer T. IDrugs 6 (2003) 137
11. Takeuchi T., Harris J.L., Huang W., Yan K.W., Coughlin S.R., and Craik C.S. J. Biol. Chem. 275 (2000) 26333
12. Ahmed S., Jin X., Yagi M., Yasuda C., Sato Y., Higashi S., Lin C.Y., Dickson R.B., and Miyazaki K. FEBS J. 273 (2006) 615
13. Sprenger C.C., Vail M.E., Evans K., Simurdak J., and Plymate S.R. Oncogene 21 (2002) 140
14. Enyedy I., Lee S.-L., Kuo A.H., Dickson R.B., Lin C.-Y., and Wang S. J. Med. Chem. 44 (2001) 1349
15. Galkin A.V., Mullen L., Fox W.D., Brown J., Duncan D., Moreno O., Madison E.L., and Agus D.B. The prostate 61 (2004) 228
16. Long Y.-Q., Lee S.-L., Lin C.-Y., Enyedy I., Wang S., Li P., Dickson R.B., and Roller P.P. Bioorg. Med. Chem. Lett. 11 (2001) 2515
17. Jiang S., Li P., Lee S.-L., Lin C.Y., Long Y.-Q., Johnson M.D., Dickson R.B., and Roller P.P. Org. Lett. 9 (2007) 9
18. Li P., Jiang S., Lee S.-L., Lin C.Y., Johnson M.D., Dickson R.B., Michejda C.L., and Roller P.P. J. Med. Chem. 50 (2007) 5976
19. Steinmetzer T., Schweinitz A., Stürzebecher A., Dönnecke D., Uhland K., Schuster O., Friedrich R., Than M.E., Bode W., and Stürzebecher J. J. Med. Chem. 49 (2006) 4116
20. Mecozzi S., West Jr. A.P., and Dougherty A. Proc. Natl. Acad. Sci. 93 (1996) 10566
21. Lin Z., and Johnson M.E. FEBS Lett. 370 (1995) 1
22. Gallivan J.P., and Dougherty D.A. Proc. Natl. Acad. Sci USA 96 (1999) 9459
23. Ettmayer P., Amidon G.L., Clement B., and Testa B. J. Med. Chem. 47 (2004) 2393
24. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Järvinen T., and Savolainen J. Nat. Rev. Drug Disc. 7 (2008) 255
25. Stürzebecher J., Prasa D., Hauptmann J., Vieweg H., and Wikström P. J. Med. Chem. 40 (1997) 3091
26. Lee K., Jung W.-H., Park C.W., Hong C.Y., Kim I.C., Kim S., Oh Y.S., Kwon O.H., Lee S.-H., Park H.D., Kim S.W., Lee Y.H., and Yoo Y.J. Bioorg. Med. Chem. Lett. 8 (1998) 2563
27. Matriptase coordinates were taken from pdb entry 2gv6, the programm Sybyl 7.3 (Tripos, St. Louis, MO) was used for building the inhibitor and assigning atom types. Docking was performed using the programm AutoDock 4 (Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. J. Comp. Chem. 1998, 19, 1639) and the graphic interface AutoDock Tools (Sanner, M.F. J. Mol. Graphics Mod. 1999, 17, 57). The picture was created using Accelrys DS Visualizer 2.0.
28. Jeffery T. Tetrahedron 52 (1996) 10113
29. Quartara L., Fabbri G., Ricci R., Patacchini R., Pestellini V., Maggi C.A., Pavone V., Giachetti A., and Arcamone F. J. Med. Chem. 37 (1994) 3630
30. All final inhibitors were purified by preparative reversed phase HPLC to more than 95% purity (detection at 220 nm) and were obtained as white powders after lyophilisation. The inhibitors were characterized by mass spectrometry and analytical reversed phase HPLC as described in reference 13.
31. Barder T.E., Walker S.D., Martinelli J.R., and Buchwald S.L. J Am. Chem. Soc. 127 (2005) 4685